Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05042193 · ClinicalTrials.gov registry record
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
A clinical trial, sponsored by Everly Health.
- Completed
- Registry status
- 1,883
- Enrollment target
NCT05042193: Completed study, sponsored by Everly Health.
NCT05042193 is a clinical trial that has completed, run by Everly Health. The registered enrollment target is 1,883 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05042193 has completed, sponsored by Everly Health.
- COMPLETED
- Registry status
- 1,883 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.
Interventions
- OTHER SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,883 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2022-06-14 |
What the finished NCT05042193 record still lists
NCT05042193 is an observational study that tracks outcomes without assigning an intervention. Its 1,883 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 is the first listed.
NCT05042193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05042193 about?
NCT05042193 is a clinical study titled "A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19". The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.
What is the current status of trial NCT05042193?
This trial is currently completed. The enrollment target is 1,883 participants. The study started on 2021-03-19. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT05042193?
The interventions under investigation include: SARS-CoV-2 (OTHER).
Who is sponsoring clinical trial NCT05042193?
This trial is sponsored by Everly Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI